Wegener, D.; Aebersold, D.M.; Grimm, M.-O.; Hammerer, P.; Froehner, M.; Graefen, M.; Boehmer, D.; Zips, D.; Wiegel, T.
Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage. Biomedicines 2022, 10, 2256.
https://doi.org/10.3390/biomedicines10092256
AMA Style
Wegener D, Aebersold DM, Grimm M-O, Hammerer P, Froehner M, Graefen M, Boehmer D, Zips D, Wiegel T.
Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage. Biomedicines. 2022; 10(9):2256.
https://doi.org/10.3390/biomedicines10092256
Chicago/Turabian Style
Wegener, Daniel, Daniel M. Aebersold, Marc-Oliver Grimm, Peter Hammerer, Michael Froehner, Markus Graefen, Dirk Boehmer, Daniel Zips, and Thomas Wiegel.
2022. "Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage" Biomedicines 10, no. 9: 2256.
https://doi.org/10.3390/biomedicines10092256
APA Style
Wegener, D., Aebersold, D. M., Grimm, M.-O., Hammerer, P., Froehner, M., Graefen, M., Boehmer, D., Zips, D., & Wiegel, T.
(2022). Postoperative Radiotherapy of Prostate Cancer: Adjuvant versus Early Salvage. Biomedicines, 10(9), 2256.
https://doi.org/10.3390/biomedicines10092256